Avelas BioSciences

29 articles about Avelas BioSciences

• 

  Five Companies Earn Validation as FDA Recognizes New Breakthrough Therapies

  12/16/2020

  Novartis' Iptacopan isn’t the only drug to receive Breakthrough Therapy designation this week. Several other experimental treatments were also awarded the designation.

• Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer Surgery

  12/14/2020

  Avelas Biosciences, Inc. , pioneering the field of intraoperative fluorescent cancer imaging, today announced that the company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for pegloprastide (AVB-620) for the intraoperative detection and visualization of positive margins during breast cancer surgery. Pegloprastide is designed to deliver a fluorescent marker to cancer cells to a

• Avelas Announces Top-Line Data Showing Pegloprastide (AVB-620) Can Significantly Improve Cancer Detection in Real Time During Breast Cancer Surgery

  8/4/2020

  Use of pegloprastide, a fluorescent cancer marker, during surgery correctly identified cancer in up to 75% of patients who would have otherwise been candidates for a repeat (re-excision) surgery Observed re-excision rate was 6% in patients whose surgeries included pegloprastide; current re-excision rates are estimated at 20-40% among all patients receiving an initial lumpectomy Each year in the U.S., more than 80,000 women undergo repeat

• Avelas Biosciences to Present at 2018 Cantor Global Healthcare Conference

  9/26/2018

  Avelas is a clinical stage oncology-focused platform technology company that is developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention.

• Avelas Biosciences Initiates Period 2 of Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

  8/2/2018

  This second portion of our Phase 2 study should enable further demonstration of the accuracy of AVB-620 in distinguishing between malignant and nonmalignant tissues

• Avelas Biosciences to Present at JMP Securities Annual Life Sciences Conference

  6/14/2018

  Avelas Biosciences, Inc. announced that Carmine N. Stengone, President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference

• Avelas Biosciences Completes Period 1 Patient Enrollment in Phase II Study of AVB-620 in Women with Primary, Nonrecurrent Breast Cancer Undergoing Surgery

  1/5/2018

  Period 1 was designed to enroll approximately 30 patients to evaluate optimal conditions to achieve differences in fluorescent signals between malignant and nonmalignant tissues.

• Avelas Biosciences Broadens Management Team with Key Executive Additions

  1/3/2018

  Avelas BioSciences today announced three new management appointments.

• Avelas Biosciences to Present at Piper Jaffray Healthcare Conference

  11/21/2017

  Avelas BioSciences today announced that Carmine N. Stengone, president and CEO, will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017, at 4:50 p.m. EST in New York City.

• Newly Published Data Supports Avelas Biosciences' Investigational Ratiometric Activatable Fluorescent Peptide AVB-620 In Intraoperative Tumor Detection

  9/27/2017

• Avelas Biosciences' AVB-620 Shows Sensitive In Vivo Visualization Of Breast Cancer In Journal Publication

  9/15/2017

• Avelas Biosciences Doses First Patient In Phase II Study Of AVB-620 In Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

  8/4/2017

• Avelas Biosciences Doses First Patient In Phase II Study Of AVB-620 In Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

  8/3/2017

• Avelas Biosciences To Participate In JMP Securities Life Sciences Conference

  6/15/2017

• Avelas Biosciences Appoints Steven Chen As Chief Medical Officer

  5/5/2017

• Avelas Biosciences To Present At Needham & Company 16th Annual Healthcare Conference

  3/30/2017

• Avelas Biosciences Appoints Alexey Vinogradov, Ph.D., To Board Of Directors

  3/14/2017

• Avelas Biosciences To Present At 29th Annual Roth Conference

  3/8/2017

• Avelas Biosciences Presents Phase 1b Clinical Trial Data For AVB-620 At 2016 San Antonio Breast Cancer Symposium

  12/8/2016

• Avelas Biosciences Announces AVB-620 Presentation At 2016 San Antonio Breast Cancer Symposium

  12/1/2016